Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
Xconomy
AUGUST 26, 2020
Dyne Therapeutics may not reach human testing until 2022, but, like many of its preclinical peers this year, the company is choosing to jump into public markets now while investor interest in the biotech sector is riding high.
111 
Let's personalize your content